Medical education review; updated 10 November 2026. Regimens must be individualized and checked against local guidelines.
Overview
Antiretroviral therapy (ART) suppresses HIV replication, restores immune function and prevents HIV-related disease. Sustained viral suppression also prevents sexual transmission. ART should be offered to everyone diagnosed with HIV and selected using resistance history, hepatitis B status, comorbidities, pregnancy considerations and interactions [1,2].
Classes and molecular mechanisms
- NRTIs: tenofovir (TDF or TAF), emtricitabine, lamivudine and abacavir inhibit reverse transcriptase after intracellular activation; they act as nucleotide/nucleoside analogues and terminate viral DNA synthesis.
- NNRTIs: doravirine, rilpivirine and efavirenz inhibit reverse transcriptase allosterically.
- INSTIs: bictegravir and dolutegravir prevent integrase-mediated insertion of viral DNA into the host genome; raltegravir is another example.
- Protease inhibitors: darunavir inhibits maturation of new virions; ritonavir or cobicistat may be used as pharmacokinetic boosters.
- Entry/attachment inhibitors: maraviroc blocks CCR5 (requires tropism testing); fostemsavir targets gp120, ibalizumab binds CD4 after attachment. Lenacapavir is a capsid inhibitor used in selected treatment settings. Some older agents are unavailable or rarely used [1].
Choosing initial treatment
In September 2026 US guidance recommends bictegravir/TAF/emtricitabine, dolutegravir plus (TAF or TDF) and (emtricitabine or lamivudine), or dolutegravir/lamivudine for appropriately screened patients [1]. Dolutegravir/lamivudine is unsuitable when hepatitis B coinfection has not been excluded, resistance results are unavailable, or rapid initiation is needed. In HBV coinfection use an ART backbone containing both tenofovir and emtricitabine or lamivudine when appropriate. Prior long-acting cabotegravir PrEP exposure raises concern for INSTI resistance; consult genotyping guidance [1].
Pharmacokinetics and interactions
TDF and TAF are distinct tenofovir prodrugs: TAF yields lower plasma tenofovir exposure but is not automatically preferred in every lipid or weight context. Many NRTIs require renal-dose assessment; abacavir is primarily hepatically metabolized. Dolutegravir is metabolized mainly through UGT1A1 and partly CYP3A; bictegravir via UGT1A1 and CYP3A. Polyvalent cations can reduce INSTI absorption: follow agent-specific separation or food instructions. Boosted protease inhibitors interact extensively through CYP3A; check statins, anticoagulants, anticonvulsants, acid suppressants and corticosteroids. Rifampicin strongly induces enzymes and can compromise ART; do not make unsupervised substitutions [2,3].
Safety and monitoring
Test HLA-B*5701 before abacavir; never rechallenge after suspected hypersensitivity. TDF may cause renal tubular or bone toxicity; TAF may be preferable in selected patients but weight and lipid changes matter. INSTI regimens can cause insomnia or weight gain in some patients. Boosted PIs may cause gastrointestinal and metabolic adverse effects. Obtain baseline HIV RNA, CD4 count, resistance genotype, hepatitis B/C tests, renal and liver tests and relevant pregnancy testing; monitor viral response and adherence [1–3].
Pregnancy and prevention
Effective ART throughout pregnancy reduces perinatal HIV transmission. Select regimens using dedicated perinatal recommendations rather than old pregnancy letter categories. HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) are distinct from treatment regimens; follow current local protocols [2].
Key takeaways
Modern HIV care favors potent, well-tolerated INSTI-based regimens for most patients, but resistance, chronic HBV, pregnancy, organ function and interactions alter the choice. Viral suppression requires sustained adherence and follow-up.
References
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Initial combination antiretroviral regimens for people with HIV. Updated 2026 Sep 24. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/what-start-initial-combination-regimens
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Principles of antiretroviral therapy. Updated 2026 Sep 24. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/principles-antiretroviral-therapy
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Antiretroviral regimen considerations for initial therapy based on specific clinical scenarios. Updated 2026 Sep 24. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/what-start-initial-antiretroviral-specific-clinical-scenarios
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.